Login to Your Account

HCV Relapses Short Circuit Gilead's ELECTRON Study

By Catherine Shaffer
Staff Writer

Tuesday, February 21, 2012

Disappointing results from Gilead Sciences Inc.'s Phase II ELECTRON study of nucleotide analogue polymerase inhibitor GS-7977 showed that six out of eight patients with a prior null response to an interferon regimen relapsed within four weeks of completing a course of GS-7977 plus ribavirin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription